Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal in a decision relating to Janssen's patent covering INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal in a decision relating to Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court of Appeal granted Janssen’s cross-appeal and dismissed Teva’s appeal, resulting in a complete victory for Janssen.
Teva Canada Limited v. Janssen Inc. - Federal Court of Appeal
